Home » Roche and Fluidigm to Co-Market 454's Sequencers, Fluidigm's Multiplexed PCR Arrays

Roche and Fluidigm to Co-Market 454's Sequencers, Fluidigm's Multiplexed PCR Arrays

Oct 19, 2010
Premium

Roche's 454 Life Sciences and Fluidigm said this week that they will co-promote their respective amplicon sample-prep and sequencing platforms.

The partnership involves 454's GS FLX and GS Junior sequencers and Fluidigm's Access Array system, which enables users to generate 48 PCR amplicons for 48 samples simultaneously.

The companies said they will offer a "robust and streamlined workflow" that minimizes the number of manual steps required for targeted sequencing applications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

What's Popular?

In Clinical Sequencing

  1. Survey Finds QC Best Practices in Clinical Genomics Still Developing

  2. Families Declining Enrollment in BabySeq Cite Lack of Interest in Research, Logistical Challenges

  3. Bristol-Myers Squibb to Use Natera's Cell-Free DNA Assay in Immunotherapy Study

  4. Nanopore Sequencing Becomes More Portable to Enable Outbreak Surveillance in Field

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.